Proactive Investors - Run By Investors For Investors

Narhex Life Sciences commences respiratory illness diagnosis app trials

Narhex Life Sciences commences respiratory illness diagnosis app trials

Narhex Life Sciences (ASX:NLS) acquisition target, ResApp Diagnostics, has enrolled its first patient at Joondalup Health Campus in Western Australia.

The trial will gather data from 150 patients with a variety of respiratory conditions with the aim of further optimising the ResApp algorithms for pneumonia and asthma.

In addition, the trial aims to broaden the validation to other common respiratory conditions such as bronchitis, bronchiolitis and upper respiratory tract conditions.

Preliminary results from this trial are expected within three months.

ResApp is currently finalising ethics approval to commence an additional trial at a second major Australian hospital that will greatly increase the speed in which patient data can be acquired.

The commencement of the trial at Joondalup Health Campus was featured on Channel 7’s Today Tonight on Monday, 23 March 2015.

ResApp, through the exclusive licence it has been granted by the University of Queensland, is developing mobile medical applications for the diagnosis and management of respiratory disease.

Addressable markets for this technology include at-home diagnosis and management of respiratory disease; licensing to large telehealth providers; and working with organisations such as the World Health Organisation to deliver tools for low-cost diagnosis and management of respiratory illness in the developing world.

Cough is the most common single reason for a doctor visit, and in the US, over 100 million primary care physician visits result in diagnosis of a respiratory disease.

According to a recent Rock Health report, US venture capital investment in mHealth for the first half of 2014 represented $2.4 billion, exceeding the total invested in 2013.


Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

View full RAP profile View Profile

ResApp Health Ltd Timeline

September 22 2017

Related Articles

A paper plane about to be launched with the help of surgical scissors
November 13 2018
The voluntarily-suspended company is progressing an ongoing recapitalisation plan.
September 25 2018
A decision on whether or not Motif can start marketing its next-generation antibiotic in the US is due by mid-February
September 25 2018
The drug developer had originally to recruit 80 people for the second part of its phase II study of its SNG001 treatment, but it will now assess 120 patients

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use